Search research articles
Contact Us
Filters
Showing results (21-30 of 28) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 28 results.
Blood
|
May 23, 1998
High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation
N Ketterer, G Salles, M Raba, et al.
British Journal of Haematology
|
October 29, 1998
Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies
N Ketterer, G Salles, I Moullet, et al.
Blood
|
September 10, 1998
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study
B Coiffier, C Haioun, N Ketterer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 21, 2006
High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults
P Pedrazzoli, J A Ledermann, J-P Lotz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 21, 2005
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
M Ghielmini, K Rufibach, G Salles, et al.
Blood
|
September 6, 2001
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
C E Dearden, E Matutes, B Cazin, et al.
Bone Marrow Transplantation
|
September 15, 2015
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
E Van Den Neste, N Schmitz, N Mounier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 14, 2012
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)
N Ketterer, B Coiffier, C Thieblemont, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 28) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 28 results.
Blood
|
May 23, 1998
High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation
N Ketterer, G Salles, M Raba, et al.
British Journal of Haematology
|
October 29, 1998
Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies
N Ketterer, G Salles, I Moullet, et al.
Blood
|
September 10, 1998
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study
B Coiffier, C Haioun, N Ketterer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 21, 2006
High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults
P Pedrazzoli, J A Ledermann, J-P Lotz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 21, 2005
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
M Ghielmini, K Rufibach, G Salles, et al.
Blood
|
September 6, 2001
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
C E Dearden, E Matutes, B Cazin, et al.
Bone Marrow Transplantation
|
September 15, 2015
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
E Van Den Neste, N Schmitz, N Mounier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 14, 2012
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)
N Ketterer, B Coiffier, C Thieblemont, et al.
Page
of 3